Phase 3Completed
Testosterone, Metformin, or Both, for Hypogonadism in Obese Males
Randomized, Double-blind, Parallel, Placebo-controlled, Clinical Trial to Assess the Efficacy of Testosterone, Metformin, or Both, for the Treatment of Obesity-induced Male Hypogonadism
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (Academic or other)
- Enrollment
- 107 enrolled
- Conditions
- Hypogonadism; Obesity
- Interventions
- Placebo; Metformin; Testosterone Undecanoate; Metformin + Testosterone Undecanoate
- Ages
- adults
- Registry
- NCT02514629
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to examine the effects of metformin, testosterone, or both, in males with obesity-related hypogonadism. This study will evaluate changes in insulin resistance, weight loss, body composition, testosterone levels,quality of life and erectile dysfunction. Obese men will receive diet and physical activity counselling, and be randomised to either testosterone, metformin, a combination of both or placebo
Primary outcomes
- Change in Insulin Resistance
History
Last registry update
Primary completion
Registered
Started